Clinical Trial Update: Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for atogepant (AGN-241689) evaluating multiple oral dosing regimens in episodic migraine prevention across Phase 2 and Phase 3; study comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Atogepant (Atogepant)

Snippet

Sponsor: Allergan | Conditions: Migraine, With or Without Aura | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2018-12-06